首页> 美国卫生研究院文献>ESMO Open >Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy

【2h】

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy

机译：一线治疗晚期卵巢癌从标准化疗转向剂量密集化疗：可行性和有效性的回顾性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundCurrent standard neoadjuvant treatment for advanced ovarian cancer is 3-weekly platinum-based chemotherapy (CP3w).Patients unable to have interval debulking surgery (IDS) or with significant residual disease have a poor outcome to CP3w treatment. We investigated the outcome in patients who were switched to dose-dense chemotherapy.

机译：背景目前用于晚期卵巢癌的标准新辅助治疗方法是每周3周的铂类化疗（CP3w），无法进行间隔减瘤术（IDS）或有明显残留疾病的患者对CP3w的治疗效果较差。我们调查了转用剂量密集化疗的患者的结局。

著录项

期刊名称 ESMO Open
作者
Andrea Milani; Rebecca Kristeleit; Mary McCormack; Fharat Raja; Daniela Luvero; Martin Widschwendter; Nicola MacDonald; Tim Mould; Adeola Olatain; Allan Hackshaw; Jonathan A Ledermann;
展开▼
作者单位

展开▼
年(卷),期 2016(1),6
年度 2016
页码 e000117
总页数 10
原文格式 PDF
正文语种
中图分类
关键词
ovarian cancer first line treatment dose dense weekly paclitaxel carboplatin and paclitaxel weekly chemotherapy;

机译：卵巢癌;一线治疗;剂量密集;每周紫杉醇;卡铂和紫杉醇;每周化疗;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study [J] . J. Vrdoljak, T. Boban, B. Petric Mi?e, Japanese journal of clinical oncology. . 2019,第4期

机译：TC剂量茂密化疗的疗效和安全性作为上皮性卵巢癌的一线治疗：一个单一的回顾队列队列研究
2. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. [J] . Aghajanian C, Fennelly D, Shapiro F, Journal of Clinical Oncology . 1998,第5期

机译：II期研究“剂量密集”高剂量化学疗法与外周血祖细胞支持作为晚期卵巢癌患者的主要治疗方法。
3. Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study. [J] . Goncalves A, Delva R, Fabbro M, Bone marrow transplantation . 2006,第7期

机译：晚期造血干细胞癌的术后序贯大剂量化疗作为一线治疗的晚期卵巢癌：II期多中心研究。
4. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
5. Integrating genomics and molecular biology: identifying transcriptional targets for the prostate cancer oncogene SOX4 and evaluating the efficacy of Aurora kinase inhibition in chemotherapy-resistant ovarian cancer [D] . Scharer, Christopher D. 2009

机译：整合基因组学和分子生物学：鉴定前列腺癌致癌基因SOX4的转录靶标并评估Aurora激酶抑制作用对化疗耐药的卵巢癌的疗效
6. Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study [O] . Tingyan Shi, Rong Jiang, Hong Pu, 2019

机译：剂量密集早期术后腹腔化疗的生存益处在晚期卵巢癌前线治疗中：随机对照研究
7. Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study [O] . A Gonçalves, R Delva, M Fabbro, 2006

机译：术后序贯高剂量化疗，血吞噬干细胞支撑载体作为晚期卵巢癌的前线治疗：II期多期一位研究

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅